Piper Jaffray Raises Price Target as Amedisys (AMED) Raises Acquisition Pipeline

November 6, 2015 11:44 AM

Piper Jaffray reiterated a Neutral rating on Amedisys (NASDAQ: AMED), and raised the price target to $45.00 (from $42.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Piper Jaffray Raises Price Target as Amedisys (AMED) Raises Acquisition Pipeline

Categories

Next Articles